Flindr Therapeutics
Flindr Therapeutics is a precision oncology therapeutics company developing first-in-class, small molecule inhibitors for cancer treatment. Their lead asset targets the RNF31 protein, and they utilize the "ImmunoGram Drug Discovery Engine" to identify and develop these inhibitors. The company focuses on translating precision targets into precision therapies to improve patient outcomes.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: €20M
Date: 24-Apr-2024
Investors: V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, Oncode Oncology Bridge Fund, Swanbridge, Brabantse Ontwikkelings Maatschappij (BOM)
Markets: Oncology, Biotechnology, Pharmaceuticals
HQ: Oss, North Brabant, Netherlands
Founded: 2020
Website: https://flindrtx.com/
LinkedIn: https://www.linkedin.com/company/flindr-therapeutics/
Twitter: https://twitter.com/FlindrT240408
Crunchbase: https://www.crunchbase.com/organization/immagene
Leave a Comment
Comments
No comments yet.